Moderna: new positive data against Omicron

(CercleFinance.com) - Moderna reports that its two bivalent booster candidates RNAm-1273.
214 and mRNA-1273.222 trigger a superior antibody response to a booster dose of its original mRNA-1273 vaccine against Omicron (BA.4/BA.5) in Phase 2/3 trials.

The biotech company added that their safety and tolerability were similar to a booster dose of mRNA-1273 and that adverse events were generally lower than the second dose of the primary series.

The RNAmessager technology specialist further adds that mRNA-1273.214 and mRNA-1273.222 also showed neutralising titers against BQ.1.1, an emerging global threat, in an exploratory analysis.


Copyright (c) 2022 CercleFinance.com. All rights reserved.